March 31st 2010 - New molecules could offer innovative treatment approach for Alzheimer’s Disease - Siena Biotech S.p.A., announced that Roche (SIX: RO, ROG; OTCQX: RHHBY) will exercise its option early to become the lead party for further development, manufacture and commercialization of certain selected candidate molecules for a better treatment of Alzheimer’s Disease.
Under the terms of the collaboration, Siena Biotech has received an undisclosed option exercise fee and is eligible for further success payments upon attainment of certain development and regulatory milestones. Following successful development and commercialization of any of the candidate compounds, Siena Biotech will also receive royalties on product sales: Siena Biotech has retained rights for the further research and development of commonly discovered novel compounds for Orphan indications... [PDF] Siena Biotech's Press Release -
